BioCentury
ARTICLE | Clinical News

ARQ 197: Phase II started

August 2, 2010 7:00 AM UTC

Kyowa Hakko began an Asian Phase II trial evaluating oral ARQ 197 in 30 patients. The start triggered a $5 million milestone payment to ArQule from Kyowa Hakko, which licensed the compound in certain ...